Phospho-Progesterone Receptor (Ser190) Antibody - #AF3742
Product: | Phospho-Progesterone Receptor (Ser190) Antibody |
Catalog: | AF3742 |
Description: | Rabbit polyclonal antibody to Phospho-Progesterone Receptor (Ser190) |
Application: | WB IHC IF/ICC |
Reactivity: | Human, Rat |
Mol.Wt.: | 99kD(Calculated). |
Uniprot: | P06401 |
RRID: | AB_2847056 |
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Cite Format: Affinity Biosciences Cat# AF3742, RRID:AB_2847056.
Fold/Unfold
NR3C3; Nuclear receptor subfamily 3 group C member 3; PGR; PR; PRA; PRB; PRGR_HUMAN; Progesterone receptor; Progestin receptor form A; Progestin receptor form B;
Immunogens
A synthesized peptide derived from human Progesterone Receptor around the phosphorylation site of Ser190.
In reproductive tissues the expression of isoform A and isoform B varies as a consequence of developmental and hormonal status. Isoform A and isoform B are expressed in comparable levels in uterine glandular epithelium during the proliferative phase of the menstrual cycle. Expression of isoform B but not of isoform A persists in the glands during mid-secretory phase. In the stroma, isoform A is the predominant form throughout the cycle. Heterogeneous isoform expression between the glands of the endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.
- P06401 PRGR_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLFPRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLAPSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAAAHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGKPRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTVMDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPDCAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLGPPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPCKAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPPYLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHNYLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPVGVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQLGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAPDLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQFEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRALSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK
PTMs - P06401 As Substrate
Site | PTM Type | Enzyme | Source |
---|---|---|---|
K7 | Sumoylation | Uniprot | |
S20 | Phosphorylation | P24941 (CDK2) | Uniprot |
S25 | Phosphorylation | P24941 (CDK2) | Uniprot |
S79 | Phosphorylation | Uniprot | |
S81 | Phosphorylation | P68400 (CSNK2A1) | Uniprot |
Y87 | Phosphorylation | Uniprot | |
S88 | Phosphorylation | Uniprot | |
S101 | Phosphorylation | Uniprot | |
S102 | Phosphorylation | Uniprot | |
S130 | Phosphorylation | Uniprot | |
S162 | Phosphorylation | P24941 (CDK2) | Uniprot |
K183 | Acetylation | Uniprot | |
K183 | Ubiquitination | Uniprot | |
S190 | Phosphorylation | P24941 (CDK2) | Uniprot |
S213 | Phosphorylation | P24941 (CDK2) | Uniprot |
S227 | Phosphorylation | Uniprot | |
S294 | Phosphorylation | P24941 (CDK2) , P28482 (MAPK1) , P27361 (MAPK3) | Uniprot |
S328 | Phosphorylation | Uniprot | |
S345 | Phosphorylation | Uniprot | |
K388 | Sumoylation | Uniprot | |
K388 | Ubiquitination | Uniprot | |
S397 | Phosphorylation | Uniprot | |
S400 | Phosphorylation | P24941 (CDK2) | Uniprot |
T430 | Phosphorylation | P24941 (CDK2) | Uniprot |
K464 | Methylation | Uniprot | |
K531 | Sumoylation | Uniprot | |
S549 | Phosphorylation | Uniprot | |
S552 | Phosphorylation | Uniprot | |
S554 | Phosphorylation | P24941 (CDK2) | Uniprot |
S558 | Phosphorylation | Uniprot | |
S561 | Phosphorylation | Uniprot | |
S666 | Phosphorylation | Uniprot | |
S676 | Phosphorylation | P24941 (CDK2) | Uniprot |
S735 | Phosphorylation | Uniprot |
Research Backgrounds
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor.
Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression of its isoform B, MR and ER. Transrepressional activity may involve recruitment of corepressor NCOR2.
Transcriptional activator of several progesteron-dependent promoters in a variety of cell types. Involved in activation of SRC-dependent MAPK signaling on hormone stimulation.
Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.
Phosphorylated on multiple serine sites. Several of these sites are hormone-dependent. Phosphorylation on Ser-294 occurs preferentially on isoform B, is highly hormone-dependent and modulates ubiquitination and sumoylation on Lys-388. Phosphorylation on Ser-102 and Ser-345 also requires induction by hormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 and Ser-400 is increased in response to progesterone and can be phosphorylated in vitro by the CDK2-A1 complex. Increased levels of phosphorylation on Ser-400 also in the presence of EGF, heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2 is ligand-independent, and increases nuclear translocation and transcriptional activity. Phosphorylation at Ser-162 and Ser-294, but not at Ser-190, is impaired during the G(2)/M phase of the cell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is required for interaction with SP1.
Sumoylation is hormone-dependent and represses transcriptional activity. Sumoylation on all three sites is enhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388, the main site of sumoylation, is repressed by ubiquitination on the same site, and modulated by phosphorylation at Ser-294.
Ubiquitination is hormone-dependent and represses sumoylation on the same site. Promoted by MAPK-mediated phosphorylation on Ser-294.
Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
Nucleus. Cytoplasm.
Note: Nucleoplasmic shuttling is both hormone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases.
Nucleus. Cytoplasm.
Note: Mainly nuclear.
Mitochondrion outer membrane.
In reproductive tissues the expression of isoform A and isoform B varies as a consequence of developmental and hormonal status. Isoform A and isoform B are expressed in comparable levels in uterine glandular epithelium during the proliferative phase of the menstrual cycle. Expression of isoform B but not of isoform A persists in the glands during mid-secretory phase. In the stroma, isoform A is the predominant form throughout the cycle. Heterogeneous isoform expression between the glands of the endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.
Interacts with SMARD1 and UNC45A. Interacts with CUEDC2; the interaction promotes ubiquitination, decreases sumoylation, and represses transcriptional activity. Interacts with PIAS3; the interaction promotes sumoylation of PR in a hormone-dependent manner, inhibits DNA-binding, and alters nuclear export. Interacts with SP1; the interaction requires ligand-induced phosphorylation on Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform A interacts with NCOR2. Isoform B (but not isoform A) interacts with NCOA2 and NCOA1. Isoform B (but not isoform A) interacts with KLF9. Interacts with GTF2B.
Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain.
Belongs to the nuclear hormone receptor family. NR3 subfamily.
Research Fields
· Cellular Processes > Cell growth and death > Oocyte meiosis. (View pathway)
· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)
· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.
· Organismal Systems > Endocrine system > Estrogen signaling pathway. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.